Laguna Bio
- Headquarters
- Berkeley, California
- Employees
- 1–10
- Founded
- 2022
- Business Model
- B2B
- Website
- lagunabio.com
- Last Round
- SeedDec 2022
About
Laguna Bio is developing next-generation cancer immunotherapy using its QUAIL platform, which is based on food-borne microbes modified to be harmless while retaining the ability to provoke a large and durable immune response. The activated immune cells generated by QUAIL can be directed to attack tumors alone or in combination with other immunotherapies that provide tumor-specific targeting, including bispecific antibodies.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account